Hot or Not, Stock Market Edition: 06/12/2025

• HOT: Eli Lilly and Company (LLY) continues to ride high on blockbuster weight-loss drugs; what’s behind recent double-digit gains for Casey’s General Stores (CASY)?
• NOT: The J.M. Smucker Company (SJM) finds itself in a jam; unpacking Apple’s (AAPL) rough year so far.

P.S. For more stocks making moves, check out our new Zen Ratings Upgrades & Downgrades screener.

A note from our sponsors...
The Best 10 AI Stocks to Own in 2025  

Discover the AI pioneer 99% of investors have never heard of... but it's one of my top picks to own now. This company has been an AI pioneer since before anyone ever heard of ChatGPT. Its sustained high double-digit growth has analysts raising price targets. Get the name-FREE.    

Discover this under-the-radar AI stock now, ahead of the crowd.

🔥 HOT: Shares of Casey’s General Stores (NASDAQ: CASY) gained 11.5% on Tuesday after the company reported solid earnings for the fiscal fourth quarter and issued strong guidance for the upcoming fiscal year. The company’s EPS for the previous quarter was $2.63, about 35% higher than Wall Street’s projection of $1.94. The report also showed that same-store sales grew by 1.7% year-over-year, and Casey’s expects it to increase another 2% to 5% in 2025. Our analysis gives Casey’s a B rating in Growth and an overall Zen Rating of B.

🥶 NOT: Shares of The J.M. Smucker Company (NYSE: SJM) fell off a cliff on Tuesday, dropping by 15.6% after a disappointing earnings report. The company’s first-quarter results were fine, beating Wall Street’s estimates by around 3.0%, but its forward guidance sent investors running for the hills. The company announced that it expects its full-year adjusted profit to be between $8.50 and $9.50 per share, a far cry from the $10.27 that Wall Street expected to see. SJM had been trading mostly flat before Tuesday’s crash, leaving it down 15.1% YTD. Our research gives SJM C ratings for all metrics besides Sentiment, which gets a modest B rating. Overall, we give SJM a C Zen Rating and a Hold recommendation.

🔥 HOT: Eli Lilly and Company (NYSE: LLY) gained 4.4% on Tuesday after the company announced a deal with Camurus to develop a new delivery system for weight-loss drugs. The company is also sitting on a potential $725 million sales boost from Mounjaro, an injectable drug that helps lower A1C levels and promote weight loss in people with diabetes. Our research gives LLY a B rating in growth, reflecting the potential the company has if Mounjaro gets enough attention from people looking for access to a weight loss injectable with a cash payment option. We tend to play it safe with pharmaceutical stocks, but LLY’s Growth potential and current Value give it a B Zen Rating and a Buy recommendation.

🥶 NOT: It’s been a rough year for Apple (NASDAQ: AAPL) so far, with the company’s stock down 18.6% YTD as of Tuesday’s close. Between the comments about Apple-specific levies from the current administration and a disappointing first day of its Worldwide Developers Conference, Apple is falling well short of other tech stocks. Our metrics have AAPL on shaky ground, with D ratings in Growth and Sentiment and C ratings in Value, Momentum, and Safety. The only saving grace for AAPL is that the company’s Financials (A rating) are as solid as ever. Apple is a traditionally cautious company, so its slow playing of AI integration in its products may not be a long-term concern. Still, given its current position, we give AAPL a C Zen Rating and a Hold recommendation.

What to Do Next?

• 200 Stocks to Sell Now >
• See All “A” Rated Stocks with +32.52% Average Annual Return >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.